Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

October 26-28, 2017

New York, New York
Sheraton New York

Commerical Activities*

Thursday, October 26, 2017

Discover the Role of Two Immunotherapies in Myeloma Treatment
Celgene Commercial Lunch Program
Program Begins: – 12:35 PM
ROOM NAME: Riverside Ballroom

NINLARO (ixazomib): an oral treatment option
Takeda Oncology Commercial Lunch Program
Program Begins: – 12:35 PM
ROOM NAME: New York Ballroom A

DARZALEX®-BASED TRIPLET THERAPY FOR MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE
In combination with Rd or Vd

Janssen Commercial Lunch Program
Program Begins: – 12:35 PM
ROOM NAME: New York Ballroom B

Saturday, October 28, 2017

The Clinical Potential of Selinexor, a first in class SINE compound in development for the treatment of patients with hematologic malignancies
Karyopharm Therapeutics Commercial Breakfast Program
Program Begins: – 6:45 AM
ROOM NAME: Riverside Ballroom

Updates in Hodgkin and T cell Lymphoma
Seattle Genetics Commercial Lunch Program
Program Begins: – 1:00 PM
ROOM NAME: Riverside Ballroom

Aliqopa (copanlisib) – a new FDA-approved therapy
Bayer Commercial Lunch Program
Program Begins: – 1:00 PM
ROOM NAME: New York Ballroom B

 

*Commercial Activities: Industry-led lectures and exhibits will be conducted in conjunction with the Lymphoma & Myeloma 2017 Congress to provide promotional product-specific information on available agents and products in development.

The above commercial activities are not a part of the Lymphoma & Myeloma 2017 Congress, nor are they organized or endorsed by Imedex®.